GSK collaborates with Alphabet to create new company, Galvani Bioelectronics

Q.  GSK has joined hands with which company focused on fighting diseases by targeting electrical signals in the body for the bioelectronics field?
- Published on 02 Aug 16

a. Google
b. Alphabet
c. Yahoo
d. Verizon

ANSWER: Alphabet
 
GlaxoSmithKline and Alphabet’s life sciences unit have created a new company focused on fighting disease by targeting electrical signals in the body, creating a new field of medicine called bioelectronics.
  • Verily Life Sciences (previously Google life sciences unit) and GSK (Britain’s biggest drugmaker) will contribute 540 million pounds over a period of 7 years to Galvani Bioelectronics.
  • New company will be based in London with a research hub in San Francisco.
  • Verily is a latest mover into creating business for Google beyond search engines.
  • Verily has other medical projects in the works including development of smart contact lenses in partnership with Swiss drugmaker Novartis which has a glucose sensor to monitor diabetes
  • Galvani is owned 55 percent by GSK and 45 percent by Verily.
  • It will develop miniaturised, implantable devices that can modify electrical nerve signals.
  • Aim is to modulate irregular/altered impulses found in many illnesses.
  • Using these tiny devices, GSK holds that diseases like asthma and diabetes could be treated.

Related Content

➨ Post your comment / Share knowledge


Enter the code shown above:

(Note: If you cannot read the numbers in the above image, reload the page to generate a new one.)
▲